CytomX Therapeutics (CTMX) Equity Average (2015 - 2026)

CytomX Therapeutics has reported Equity Average for 12 years, with the latest figure at $209.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 1603.54% year-over-year to $209.5 million; the trailing twelve-month figure through Mar 2026 stood at $209.5 million (up 1603.54% YoY), and the FY2025 full-year result was $49.3 million, up 305.73% from the prior year.
• Equity Average for Q1 2026 stood at $209.5 million, up from $103.2 million in the prior quarter.
• The five-year high for Equity Average was $209.5 million in Q1 2026, with the low at -$86.2 million in Q1 2023.
• Historically, Equity Average has averaged -$5.7 million across 5 years, with a median of -$31.5 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average tumbled 654.8% — and 2026, when it surged 1603.54%.
• CytomX Therapeutics' Equity Average stood at -$83.1 million in 2022, then soared by 40.66% to -$49.3 million in 2023, then jumped by 75.77% to -$12.0 million in 2024, then jumped by 963.3% to $103.2 million in 2025, then jumped by 102.98% to $209.5 million in 2026.
• The last three Equity Average figures came in at $209.5 million (Q1 2026), $103.2 million (Q4 2025), and $113.6 million (Q3 2025), per Business Quant data.